Skip To Main Content
Hideki T. Miyazaki on Muck Rack

Hideki T. Miyazaki

As seen in: Nature, Chinese Clinical Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Hideki T.

Contact Hideki T., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Anomalous enhancement of thermoelectric power factor in multiple two-dimensional electron gas system - Nature Communications

|
By Takafumi Ishibe, Takaaki Mano, Akihiro Ohtake, Hideki T. Miyazaki, Takeshi Kasaya, Yuto Uematsu
| Nature Verified
Abstract Toward drastic enhancement of thermoelectric power factor, quantum confinement effect proposed by Hicks and Dresselhaus has intrigued a lot of researchers. There has been much effort to increase power factor using step-like density-of-states in two-dimensional electron gas (2DEG) system.
Open in Who Shared Issue with article?

A case of pseudomyxoma peritonei successfully treated with trifluridine/tipiracil (TAS-102) and bevacizumab after palliative debulking surgery

|
By Hideki T. Miyazaki, Yoshimasa Gohda, Nami Hayama
| Chinese Clinical Oncology Verified
A case of pseudomyxoma peritonei successfully treated with trifluridine/tipiracil (TAS-102) and bevacizumab after palliative debulking surgery Satoshi Hirano, Yoshimasa Gohda, Hideki Miyazaki, Nami Hayama, Shinichiro Shimizu, Toru Igari, Hideaki Yano
Open in Who Shared Issue with article?

A case of pseudomyxoma peritonei successfully treated with trifluridine/tipiracil (TAS-102) and bevacizumab after palliative debulking surgery

|
By Yoshimasa Gohda, Hideki T. Miyazaki, Nami Hayama
| Chinese Clinical Oncology Verified
Case Report Introduction Pseudomyxoma peritonei (PMP) is a rare disease with a reported prevalence of about 1–3 per million people annually (1). Cytoreductive surgery (CRS) and perioperative hyperthermic intraperitoneal chemotherapy (HIPEC) are considered as treatment options allowing improved disease control and better long-term survival (2,3).
Open in Who Shared Issue with article?
See all 4 articles